Myotonic dystrophy type 1 (DM1) is an autosomal dominant multisystem disorder resulting from an unstable trinucleotide (CTG)n repeat expansion in the 3’ untranslated region of the dystrophia myotonica‐protein kinase (DMPK) gene.1 Clinical manifestations of DM1 include progressive muscle weakness and wasting, myotonia, premature cataracts, cardiac conduction defects, gastrointestinal/endocrine abnormalities, and increased risk of certain cancers.2, 3 It has been suggested that the DM1 phenotypes may resemble a premature aging syndrome.4 This evidence concerns the gene DMPK and myotonic dystrophy type 1.